Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.